The main purpose of this legislation is to empower the Federal Trade Commission (FTC) to take action against the misuse of citizen petitions that aim to obstruct the approval of competing generic drugs or biosimilars. The goal is to promote competition in the pharmaceutical market and ensure that legitimate public health concerns can still be raised without being hindered by frivolous petitions. Key provisions of the legislation include defining what constitutes a "sham" petition, which is one that is baseless and intended to interfere with a competitor's business.